首页> 外文OA文献 >How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension
【2h】

How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension

机译:如何提高抗高血压药物治疗的疗效和依从性:高血压中二氢吡啶并钙通道阻滞剂的核心作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Essential hypertension is a complex clinical condition, characterized by multiple and concomitant abnormal activation of different regulatory and contra-regulatory pathophysiological mechanisms, leading to sustained increase of blood pressure (BP) levels. Asymptomatic rise of BP may, indeed, promote development and progression of hypertension-related organ damage, which in turn, increases the risk of major cardiovascular and cerebrovascular events. A progressive and independent relationship has been demonstrated between high BP levels and increased cardiovascular risk, even in the high-to-normal range. Conversely, evidence from randomized controlled clinical trials have independently shown that lowering BP to the recommended targets reduces individual cardiovascular risk, thus improving event-free survival and reducing the incidence of hypertension-related cardiovascular events. Despite these benefits, overall rates of BP control remain poor, worldwide. Currently available guidelines support a substantial equivalence amongst various antihypertensive drug classes. However, several studies have also reported clinically relevant differences among antihypertensive drugs, in terms of both BP lowering efficacy and tolerability/safety profile. These differences should be taken into account not only when adopting first-line antihypertensive therapy, but also when titrating or modulating combination therapies, with the aim of achieving effective and sustained BP control. This review will briefly describe evidence supporting the use of dihydropyridinic calcium channel blockers for the clinical management of hypertension, with a particular focus on barnidipine. Indeed, this drug has been demonstrated to be effective, safe and well tolerated in lowering BP levels and in reducing hypertension-related organ damage, thus showing a potential key role for improving the clinical management of hypertension.
机译:原发性高血压是一种复杂的临床疾病,其特征是多种不同的调节和反调节病理生理机制伴随并异常激活,从而导致血压(BP)水平持续升高。血压的无症状升高确实可以促进高血压相关器官损害的发生和发展,进而增加发生重大心血管和脑血管事件的风险。即使在高至正常范围内,高血压水平与心血管风险增加之间也已显示出一种渐进和独立的关系。相反,来自随机对照临床试验的证据独立显示,将BP降低至推荐的靶标可降低个体心血管疾病的风险,从而提高无事件生存率并降低高血压相关心血管事件的发生率。尽管有这些好处,但全世界范围内的BP控制率仍然很差。当前可用的指南支持各种降压药类别之间的实质等效。但是,一些研究还报告了降压药在临床上的相关差异,包括降压效果和耐受性/安全性方面。这些差异不仅应在采用一线抗高血压治疗时考虑到,而且在滴定或调整联合治疗时也应考虑到,以实现有效和持续的BP控制。这篇综述将简要描述支持二氢吡啶酮钙通道阻滞剂用于高血压临床治疗的证据,特别关注巴尼地平。实际上,已证明该药物在降低血压水平和减少高血压相关器官损害方面是有效,安全且耐受性良好的,因此在改善高血压的临床管理方面显示出潜在的关键作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号